Anne Frey Luetkemeyer MD
Assistant Professor, Medicine, UCSF School of Medicine
Join to View Full Profile
995 Potrero AveBox 0874San Francisco, CA 94110
Phone+1 415-476-4082
Fax+1 415-476-6953
Dr. Luetkemeyer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Infectious Disease, 2003 - 2006- University of California (San Francisco)Residency, Internal Medicine, 1999 - 2002
Harvard Medical SchoolClass of 1999
Certifications & Licensure
CA State Medical License 2001 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection Start of enrollment: 2008 Apr 01
- A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C Start of enrollment: 2014 Aug 01
- Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men Start of enrollment: 2019 Nov 26
Publications & Presentations
PubMed
- 1 citationsDoxycycline to prevent bacterial sexually transmitted infections in the USA: final results from the DoxyPEP multicentre, open-label, randomised controlled trial and op...Anne F Luetkemeyer, Deborah Donnell, Stephanie E Cohen, Julia C Dombrowski, Cole Grabow
The Lancet. Infectious Diseases. 2025-03-24 - 2 citationsIn Vitro Exposure of Treponema pallidum to Subbactericidal Doxycycline Did Not Induce Resistance: Implications for Doxycycline Postexposure Prophylaxis.Lauren C Tantalo, Anne F Luetkemeyer, Nicole A P Lieberman, B Ethan Nunley, Carlos Avendaño
The Journal of Infectious Diseases. 2025-03-17 - Another Tool for the Sexual Health Toolkit: US Health Care Provider Knowledge and Attitudes About Doxycycline Postexposure Prophylaxis to Prevent Bacterial Sexually Tr...Rodney Perkins, Kristin Beima-Sofie, Katerina Christopoulos, Stephanie E Cohen, Aurnell Dright
Sexually Transmitted Diseases. 2025-03-01
Press Mentions
Antibiotic Cuts Risk of HIV, STDs After Exposure, Study SaysMay 8th, 2023- Doxy-PEP for STIs and More: Dr. Dieffenbach’s Highlights from Day 1 of CROI 2023February 21st, 2023
- Meta-Analysis Supports COVID-19 Mortality Benefit with IL-6 InhibitorsJuly 15th, 2021
- Join now to see all
Grant Support
- The Doxy-PEP Impact Study: a multi-city US longitudinal cohort to evaluate doxy-PEP field effectiveness, investigate associated antimicrobial resistance, and establish doxy-PEP to need ratiosUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2029
- Evaluation of doxycycline post-exposure prophylaxis to reduce sexually transmitted infections in PrEP users and HIV-infected men who have sex with menUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2019–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
